Breaking News

Baxter Acquires Hemophilia Assets

January 24, 2013

Gains investigational compound OBI-1 and related assets

Baxter International has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, in conjunction with Inspiration’s ongoing bankruptcy proceedings. The transaction, which includes manufacturing operations from Ipsen Pharma, is subject to regulatory approvals.
 
Baxter will make an upfront payment of $50 million and may make payments of as much as $20 million based on regulatory approval in the U.S. and its first additional country. Additional amounts may be paid upon approval of additional indications, sales payments and milestones when sales exceed $100 million. 
 
OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for the treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors. OBI-1 is currently in Phase III studies and has received orphan drug designation in the U.S. and Europe, and was recently granted fast track designation by the FDA.
 
“OBI-1 has the potential to address existing unmet needs of hemophilia patients and is a strong strategic fit with Baxter’s current hemophilia portfolio,” said Bruce Ewenstein, M.D., Ph.D., vice president of clinical affairs in Baxter’s BioScience business.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent